|
|
 |
 |
 |
|
Kevin Slawin, MD
(Founder, President and Chief Medical Officer),
Director of the Vanguard Urologic Institute and the Texas Prostate Center, recently left his position as the Dan L. Duncan Professor, Scott Department of Urology, Baylor College of Medicine and Director of The Baylor Prostate Center, a position he held since 1994. He is also Director of Urology at Memorial Hermann Hospital - TMC and a member of the Center for Clinical and Translational Sciences, a collaboration between University of Texas Health Sciences Center and Memorial Hermann Hospital - TMC.
|
|
|
|
Thomas J. Farrell (Chief
Executive Officer),
was founding President & CEO of Cylene Pharmaceuticals, Inc, San Diego, CA, a company developing a novel class of small molecules as anti-cancer therapy, currently in Phase II clinical trials. He received his M.B.A. at Stanford Graduate School of Business, where he was an Arjay Miller Scholar..
|
|
|
|
David M. Spencer, Ph.D.
(Chief Scientific Officer),
is Associate Professor of Immunology, Baylor College of Medicine, inventor on numerous patents, including Chemical Inducer of Dimerization (CID) technology used in over 1000 labs worldwide and a core technology for ARIAD Pharmaceuticals, Inc. Recently awarded the Michael E. DeBakey Excellence in Research Award at Baylor College of Medicine, he has made key breakthroughs in enabling technologies for safer, regulated gene therapy..
|
|
|
|
|
|
